Hypoglycemic Drugs Market
- 2026 年市場規模
- USD 905.2 Mn
- 2033 年預估規模
- USD 1,270.6 Mn
- 年複合成長率 CAGR
- 9.6%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Hypoglycemic Drugs Market, By Drug Class (Sulphonylureas, Biguanides, Alpha-glucosidase inhibitors, Thiazolidinediones, Dipeptidyl peptidase-4 (DPP-4) inhibitors, Glucagon), By Route of Administration (Oral, Injectable, Nasal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
Hypoglycemia is a condition in which blood sugar (glucose) level is lower than the standard range. Glucose is the main energy soiurce for the body. Hypoglycemia is often related to diabetes treatment. Hypoglycemia occurs when the level of glucose present in the blood falls below a set point, i.e., below 4 mmol/L (72mg/dL). The symptoms associated with Hypogyclemia are, sweating, fatigue, feeling dizzy, feeling weak, blurred vision, and others. Hypoglycemia is detected by measuring blood sugar levels with a glucose meter. Any blood glucose level below 4.0 mmol/L indicates that the individual has hypoglycemia.
Market Dynamics
Increasing prevalence of diabetes is expected to drive growth of the global hypoglycemic drugs market. For instance, according to an article published by American Diabetes Association on 28 July 2022, in 2019, 37.3 million Americans, or 11.3% of the population, had diabetes. Nearly 1.9 million Americans had type 1 diabetes, including about 244,000 children and adolescents. 1.4 million Americans are diagnosed with diabetes every year.according to same soruce, In 2014–2015, the annual incidence of diagnosed diabetes in youth was estimated at 18,200 with type 1 diabetes and 5,800 with type 2 diabetes.
Increasing number of drug approvals from regulatory bodies is expected to drive growth of the global hypoglycemic drugs market. For instance, in December 2020, Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its Abbreviated New Drug Application for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid.
Key features of the study
• This report provides an in-depth analysis of the global hypoglycemic drugs market, provides market size (USD Mn), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global hypoglycemic drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
• Key companies covered as a part of this study include Eli Lilly & Company, Boehringer Ingelheim GmbH, Vistin Pharma AS, Janssen Pharmaceuticals NV, Sanofi, Astellas Pharma Inc., AstraZeneca plc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Teva Pharmaceuticals Pvt Ltd., and Sun Pharmaceutical Industries Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global hypoglycemic drugs market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global hypoglycemic drugs market
Market Segmentation
• Global Hypoglycemic Drugs Market, By Drug Class
o Sulphonylureas
o Biguanides
o Alpha-glucosidase inhibitors
o Thiazolidinediones (Glitazones)
o Dipeptidyl peptidase-4 (DPP-4) inhibitors
o Glucagon
• Global Hypoglycemic Drugs Market, By Route of Administration
o Oral
o Injectable
o Nasal
• Global Hypoglycemic Drugs Market, By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• Global Hypoglycemic Drugs Market, By Region
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
o Asia Pacific
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Eli Lilly & Company,
o Boehringer Ingelheim GmbH,
o Vistin Pharma AS,
o Janssen Pharmaceutica NV,
o Sanofi, Astellas Pharma Inc.,
o AstraZeneca plc.,
o Merck & Co., Inc.,
o Novartis AG.,
o Novo Nordisk A/S,
o Teva Pharmaceuticals Pvt Ltd.,
o Sun Pharmaceutical Industries Ltd
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snippet, By Drug Class
Market Snippet, By Route of Administration
Market Snippet, By Distribution Channel
Market Snippet, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o List of Distributors
o Key Developments
o PEST Analysis
o Regulatory Scenario
o New Product Launch/ Approval
o Acquisition and Partnership Scenario
o Market Trends
4. Global Hypoglycemic Drugs Market, By Drug Class, 2026-2033 (USD Mn)
o Introduction
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2026-2033
Segment Trends
o Sulphonylureas
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
o Biguanides
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
o Alpha-glucosidase inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
o Thiazolidinediones
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
o Dipeptidyl Peptidase-4 (DPP-4) inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
o Glucagon
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
5. Global Hypoglycemic Drugs Market, By Route of Administration, 2026-2033 (USD Mn)
o Introduction
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2026-2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
o Injectable
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
o Nasal
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
6. Global Hypoglycemic Drugs Market, By Distribution Channel, 2026-2033 (USD Mn)
o Introduction
Market Share Analysis, 2022 and 2030 (%)
Y-o-Y Growth Analysis, 2026-2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Mn)
7. Global Hypoglycemic Drugs Market, By Region, 2026 - 2033 (USD Mn)
o Introduction
Market Share Analysis, By Region, 2022 and 2030 (%)
Y-o-Y Growth Analysis, For Regions, 2026-2033
Regional Trends
o North America
Introduction
Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, By Country, 2026-2033 (USD Mn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, By Country, 2026-2033 (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, By Country, 2026-2033 (USD Mn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, By Country, 2026-2033 (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, By Country, 2026-2033 (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, By Drug Class, 2026-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2026-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2026-2033 (USD Mn)
Market Size and Forecast, By Country/ Region, 2026-2033 (USD Mn)
o South Africa
o Central Africa
o North Africa
8. Competitive Landscape
o Company Profiles
Eli Lilly & Company
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Boehringer Ingelheim GmbH
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Vistin Pharma AS
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Janssen Pharmaceuticals NV
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Sanofi
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Astellas Pharma Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
AstraZeneca plc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Merck & Co., Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Novartis AG
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Novo Nordisk A/S
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Teva Pharmaceutical Pvt. Ltd.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
Sun Pharmaceutical Industries Ltd.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們